Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Lipitor party over but olmesartan solid for Daiichi Sankyo

This article was originally published in Scrip

Executive Summary

Ranbaxy and its owner Daiichi Sankyo may have benefited handsomely from the 180-day first-to-file US exclusivity for the Indian firm's generic version of Lipitor (atorvastatin) when it was launched in December 2011, but the hangover is hitting with a vengeance this year.

Topics

Related Companies

UsernamePublicRestriction

Register

SC022301

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel